Sage Geosystems Partners with NREL and Romania’s Electrocentrale Bucuresti (ELCEN) to Conduct Feasibility Study on Decarbonizing District Heating System in Bucharest
24.7.2024 09:00:00 EEST | Business Wire | Press release
Sage Geosystems Inc. (Sage), a geothermal and energy storage company, announced today that it will be partnering with Electrocentrale Bucuresti S.A. (ELCEN), Romania’s leading producer of thermal and electrical energy in Bucharest. This partnership will explore how geothermal energy can be implemented within the city of Bucharest to replace a fossil-fuel based thermal plant with a clean, reliable alternative energy source. The first project will generate up to 70MW thermal power for a district in Bucharest and upon its success will be expanded to other Romanian projects and cities.
Sage will rely on its field-proven Geopressured Geothermal System (GGS) technology, which maximizes the heat harvested and minimizes cost. A feasibility study will be performed in partnership with the National Renewable Energy Laboratory (NREL).
“Sage is thrilled to be supporting Romania’s transition to clean energy and to introduce geothermal energy applications to its capital city,” said Cindy Taff, CEO and co-founder of Sage Geosystems. Lev Ring, President and co-founder of Sage Geosystems, added “We are proud to be involved with NREL, the U.S. Department of Energy (DOE) and the Partnership for Transatlantic Energy and Climate Cooperation (P-TECC) and we are looking forward to the many partnerships and advancements we will develop in Europe as a result of this program.”
The general director of ELCEN, Claudiu Crețu, shared at the Profit Energy.forum in October 2023, that the company would be conducting studies to see if it can use the geothermal heat from underneath Bucharest for the centralized heating of the Capital.
ELCEN currently produces 40 percent of Romania’s and 90 percent of Bucharest’s thermal energy for district heating, and implementing a renewable energy source like geothermal would significantly reduce carbon emissions throughout the city and the country.
For more information, please visit www.sagegeosystems.com.
About Sage Geosystems Inc.
Sage Geosystems was founded in 2020 and is developing energy storage and geothermal baseload technologies deep in the earth. The Sage Geosystems team has over 150 combined years in the oil and gas industry, with experience delivering major projects including Deepwater, Arctic, and Unconventional shales. The company is headquartered in Houston, Texas. For more information, visit www.sagegeosystems.com.
About Electrocentrale Bucuresti S.A.
ELCEN is both an electricity producer and a heat energy producer. It is the largest thermal (heat) energy producer in Bucharest, Romania as well as nationwide. Founded in 2002, ELCEN is a subsidiary of Termoelectrica S.A.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240723000910/en/
Contacts
Brad Carl
brad@teamsilverline.com
(253) 318-6852
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CorFlow Therapeutics Announces Successful Completion of Phase 1 and First Patients Enrolled in Phase 2 of the MOCA II Pivotal Trial, Approval to Start the REVITALISE RCT in Europe, and Strengthening of Clinical Leadership30.4.2026 14:00:00 EEST | Press release
CorFlow Therapeutics AG (CorFlow), a clinical-stage company focused on transforming the diagnosis and treatment for heart attack patients, today announced multiple milestones in advancing its clinical program and the strengthening of clinical leadership. Phase 1 of the company’s MOCA II FDA Pivotal Trial was successfully reached after safety and performance goals were met with STEMI heart attack patients who had the proprietary PCoFI diagnostic measurement of microvascular obstruction (MVO) made during a stenting procedure, when compared to the reference standard diagnosis by cardiac MRI in the subsequent days. Phase 1 included 19 patients enrolled across 5 US and 3 European sites. MOCA II follows the FIH MOCA I study and primarily aims to validate the threshold value of the proprietary PCoFI measurement for diagnosing MVO in the setting of primary angioplasty compared to cardiac MRI. This milestone achievement, which was confirmed by the study’s independent DSMB (Data and Safety Monit
Agendia to Present New Data Demonstrating the Expanded Clinical Utility of MammaPrint ® and BluePrint ® at the 2026 ESMO Breast Cancer Annual Congress30.4.2026 14:00:00 EEST | Press release
Agendia®, Inc., a leader in precision oncology for breast cancer, today announced it will present new data at the 2026 European Society for Medical Oncology (ESMO) Annual Congress on Breast Cancer, taking place May 6-8 in Berlin, Germany. The company will present two posters featuring data from the prospective FLEX Study and an independent post hoc analysis of the landmark MINDACT trial that underscore the prognostic value of MammaPrint® + BluePrint® in early-stage breast cancer (EBC). Poster #65P | Thursday, May 7, 13:15 – 14:15 p.m. CEST | Presenter: Elena Shagisultanova Prognostic Performance of MammaPrint in Patients with Small T1a, b, and c Node-Negative Early Breast Cancer A retrospective analysis from the FLEX Study involving 4,349 patients highlights the biological heterogeneity within small, node-negative (T1a, b, and c) tumors – a group that typically has favorable outcomes. MammaPrint (MP) identified a High Risk 2 (H2) subset, representing 10% of all patients and 5% of those
The Biggest Predictor of Business Growth Is Behavior30.4.2026 10:00:00 EEST | Press release
IDEO, the global design and innovation company, today announced the IDEO Innovation Quotient (IDEO IQ), a new report measuring how workplace behaviors drive business performance across 100 of the world’s largest companies. Those with the highest IDEO IQ scores earned nearly $20 billion in profit last year—50% higher than average and three times more than those ranked at the bottom. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429978890/en/ The IDEO Innovation Quotient (IDEO IQ) is a new report measuring how workplace behaviors drive business performance across 100 of the world’s largest companies. The IDEO IQ surveyed 266 leaders in product and innovation roles at 100 of the world’s largest companies across the Media & Technology, Healthcare, and Consumer Goods sectors. The report is the first of its kind to draw a direct line between how companies operate internally and their financial performance. Companies were surve
Suzano Sells 12.7 Million Tonnes of Pulp for the First Time in Its History30.4.2026 01:22:00 EEST | Press release
Suzano(B3: SUZB3 | NYSE: SUZ), the world’s largest pulp producer, announces its results for the first quarter of 2026 (1Q26), achieving a new all‑time record in pulp sales. Over the 12‑month period from April 2025 to March 2026, the company sold 12.7 million tonnes of pulp, the highest volume ever recorded in its history. During the same period, Suzano also sold 1.7 million tonnes of paper across the packaging, printing and writing, specialty, and tissue segments. This unprecedented sales level mainly reflects the increase in production capacity following the start‑up of the Ribas do Rio Pardo pulp mill in the state of Mato Grosso do Sul, as well as Suzano’s strong operational efficiency across its production lines and supply chains, serving customers in more than 100 countries worldwide. In the first quarter of 2026, Suzano sold a total of 3.2 million tonnes, comprising 2.8 million tonnes of pulp and 378 thousand tonnes of paper. Net revenue amounted to BRL 11.0 billion, while adjuste
The Estée Lauder Companies Announces Minority Investment in Luxury Clinical Skin Care Brand 111SKIN29.4.2026 23:30:00 EEST | Press release
The Estée Lauder Companies Inc. (NYSE:EL) today announced a minority investment in 111SKIN, a luxury clinical skin care brand founded by renowned plastic and reconstructive surgeon Dr. Yannis Alexandrides. Terms of the investment were not disclosed. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429495879/en/ 111SKIN's Reparative Collection Founded in 2012, 111SKIN was originally developed by Dr. Alexandrides to accelerate his patients’ healing time following procedures. At the heart of the brand is its innovative NAC Y2™, a pioneering complex designed to support skin repair and maintain a healthy, radiant and resilient complexion. Building on the foundation of this clinical expertise, 111SKIN has developed a portfolio of more than 30 products, anchored by its Black Diamond and Reparative collections and priced from $50 to $1,000. “Skin care is entering a new phase, shaped by the convergence of procedures, longevity and b
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom